<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895323</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000636332</org_study_id>
    <secondary_id>CMMI-C-071A-07</secondary_id>
    <nct_id>NCT00895323</nct_id>
  </id_info>
  <brief_title>Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer</brief_title>
  <official_title>Phase I Study of Preoperative Detection of Colorectal Carcinoma With Bispecific Antibody Pretargeting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Garden State Cancer Center at the Center for Molecular Medicine and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as radionuclide imaging using bispecific antibody, may
      help find colorectal cancer cells and learn the extent of disease.

      PURPOSE: This phase I trial is studying how well a bispecific antibody works in finding tumor
      cells in patients with colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Assess the pharmacokinetics and tissue distribution of anti-CEA x anti-HSG bispecific
           monoclonal antibody TF2 in patients with colorectal cancer.

      OUTLINE: This is a multicenter study.

      Patients receive iodine I 131-labeled anti-CEA x anti-HSG bispecific monoclonal antibody TF2
      (^131I-TF2) IV over 10-20 minutes on day 1. Patients also undergo whole-body external
      scintigraphy at various times during the study.

      Blood samples are collected at baseline and periodically after ^131I-TF2 infusion for
      pharmacokinetic studies and ^131I-TF2 biodistribution by ELISA and radioactivity
      measurements.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue distribution</measure>
  </primary_outcome>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enzyme-linked immunosorbent assay</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>whole-body scintigraphy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal cancer

               -  Radiological documentation of disease is preferred, but not required

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Life expectancy ≥ 3 months

          -  WBC ≥ 3,000/mm³

          -  Neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Serum creatinine normal

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST/ALT &lt; 2 times ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 1 month after
             completion of study therapy

          -  No medical conditions that might prevent full participation in protocol-required
             testing or follow-up

          -  No institutionalized patients (e.g., in prisons or mental health institutions)

        PRIOR CONCURRENT THERAPY:

          -  No concurrent chemotherapy or treatments that would compromise the safety and efficacy
             of protocol assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiwu R. He, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lombardi Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Lombardi Comprehensive Cancer Center</last_name>
      <phone>202-444-0381</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <name_title>Sylvia Gargiulo</name_title>
    <organization>Garden State Cancer Center and Center for Molecular Medicine and Immunology</organization>
  </responsible_party>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

